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38 months (range: 2-95), 4 patients (9.1%) had a local relapse 
(LR) after a median time of 10 months (range: 1-26). All 
relapses occurred in T2 tumors, with 3 out of 4 presenting 
with an initial tumor size > 2.5 cm. No nodal or metastatic 
progression were observed. The actuarial 4-year LR free-
survival and colostomy free-survival were 88.7%. Overall, 5 
cases of acute grade 3 skin toxicity (4 perianal and 1 inguinal) 
and 4 cases of acute grade 3 diarrhoea were observed. No 
late grade ≥ 3 toxicity was reported. 
Conclusions: In early stage node negative anal cancers (T1-2 
measuring ≤3cm, with ≤ 50% anal circumference 
involvement), highly conformal RT techniques provide 
excellent LRC rates with an acceptable toxicity profile, at 
least comparable to those published in the literature, 
especially using a brachytherapy boost. PII to 36 Gy delivered 
with modern EBRT techniques may significantly reduce the 
risk of inguinal relapse without increasing radiation-induced 
side effects.  
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Purpose/Objective: This retrospective study evaluates the 
utility of a 3-Tesla (3T) MRI in detecting a local recurrence or 
nodal involvement in post-prostatectomy prostate cancer 
patients receiving adjuvant or salvage intensity modulated 
radiation therapy (IMRT). 
Materials and Methods: From 1/1/2006 to 5/1/2012, 90 
patients status post prostatectomy had a 3T MRI prior to 
adjuvant or salvage IMRT. Patients were grouped into those 
with positive and negative findings on MRI. The following 
variables were analyzed for their usefulness in predicting 
positive findings on MRI: pre- and post-op PSA, PSA and 
testosterone at time of imaging, PSA velocity, surgical 
margins, Gleason grade, stage, physical exam findings, and 
type of surgical prostatectomy. 
Results: Significant variables predictive of a positive MRI 
included positive margins and presence of a positive digital 
rectal exam. Furthermore, the anatomical site of tumor 
recurrence on 3T MRI was significantly associated with the 
anatomical locations of positive margins. In the vast majority 
of patients with a positive 3T MRI, imaging aided in IMRT 
treatment planning. Patients with a positive MRI finding, as 
compared without MRI findings, did not show differences in 
clinical outcome at follow-up. 
Conclusions: A pre-RT 3T MRI is useful to assess recurrences 
in prostate cancer in post-prostatectomy men with rising PSA 
levels. In order to ensure cost-effectiveness of the 3T MRI, 
assessment of tumor margins and a careful physical 
examination must be performed in order to optimize the 
chance of a positive MRI finding and thus guide treatment 
planning.  
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Purpose/Objective: The role of 18F-choline positron emission 
tomography/computed tomography (Cho- PET) in diagnosis 
and staging before definitive radiotherapy in localized 
prostate cancer patients is not standardized. Aim of the 
study is to evaluate the impact of Cho- PET decision making 
strategy in patients with localized prostate cancer eligible to 
definitive radiotherapy. 
Materials and Methods: From January 2011 to August 2014, 
sixty patients with biopsy proven prostate adenocarcinoma, 
with no prior treatment on primary tumor and staged with 
Cho-PET before radiotherapy were prospectively enrolled. 
Median age was 73 years (60-81 years); Gleason score was 6 
in 32 patients (pts), 7 in 14 pts and ≥8 in 14 pts; median PSA 
value at the diagnosis was 6.79 ng/ml (2.3-143ng/ml). All 
patients were treated with Volumetric Modulated Arc 
Therapy (Varian RapidArc®, Palo Alto - CA, USA) with 
simultaneous integrated boost in 28-30 fractions (moderate 
hypofractionation) as follow: for low risk prostate PTV only, 
for intermediate risk prostate and seminal vesicles PTVs and 
for high risk prostate, seminal vesicles and pelvic lymph 
nodes. Androgen deprivation was prescribed according to 
NCCN risk classification. Cho-PET findings were used to 
define the stage according to the detection of primary tumor 
(T), pelvic lymph nodes (N) and distant metastases (M). 
Therapeutic strategy based on the Cho-PET evaluation was 
compared to the strategy that would have been proposed in 
case of PET not available and/or not strictly indicated, 
following international and national prostate cancer 
guidelines. 
Results: Cho-PET was positive in 57 cases (95%): T (prostate 
gland only) in 46 (81% of all positive cases); T in combination 
with N( pelvic nodes) in 7 (12.5%); and M(bone) in 
combination with T or N, or both, in 4 (6.5%). After the Cho-
PET patients were stratified according to NCCN risk 
classification as follows: 26 (43%) low risk, 10 (16%) 
intermediate risk and 24 (41%) high risk. Cho-PET shifted 
treatment indication in 13 cases (21%). The changes 
regarding radiation treatment volumes were as follow: 6 
intermediate risk pts (10%) shifted to high risk and 
consequently were irradiated on prostate, seminal vesicles 
and pelvic nodes PTVs; in 7 high risk pts (11%) the Cho-PET 
showed bone and/or pelvic lymph node uptake and 
consequently a simultaneous integrated boost on PET positive 
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sites was prescribed. No upstaging of low risk patients to a 
higher risk was observed. 
Conclusions: Our results have shown that Cho-PET seem to 
be a promising diagnostic tool in prostate cancer patients 
who are candidates to radical radiotherapy and supporting 
the decision making in treatment planning, in particular in 
intermediate-high risk. Although a simultaneous integrated 
boost on Cho-PET positive sites is still under investigation, it 
could be a possible option to intensify local radiation 
treatment in this setting. 
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Purpose/Objective: Endorectal balloons (ERBs) can be used 
for the stabilisation of the prostate during radical external 
beam radiotherapy (EBRT). By reducing positional 
uncertainties, the internal margin may be decreased, 
reducing overall PTV volume. Studies have demonstrated 
reduced prostate motion, but the effect of ERBs on the 
seminal vesicles (SV) is less well reported. We aim to quantify 
ERB effect on seminal vesicle positioning.  
Materials and Methods: Eight consecutive patients were 
chosen from a local prospective study into the feasibility of 
using ERBs in prostate EBRT practice. Patients eligible for the 
study were those undergoing radical EBRT as their primary 
treatment modality for localised prostate cancer. Planning 
scans were performed supine, bladder empty, with and 
without a 100cc air filled RectalPro ERB. Contouring was 
undertaken using Pinnacle (Version 9.6). The maximum A-P 
overlap between rectum and seminal vesicle was measured as 
distance from anterior rectal wall to posterior extent of SV 
(see Figure 1 for technique). This was measured for left and 
right SVs then averaged. Maximum lateral spread of seminal 
vesicles was measured on the slice demonstrating maximum 
distance between the lateral edges of the left and right 
seminal vesicles. Superior-inferior SV extent was measured 
from base to tip of seminal vesicles and averaged between 
left and right sides. Two-tailed, paired Student's T-tests were 
used to compare the ERB and no-ERB data. 
Results: Maximum A-P overlap of the SV and rectum was 
significantly greater with an ERB in-situ than without (Mean: 
1.78cm versus 0.65cm, p<0.001). Maximum lateral separation 
of the SV was significantly greater with an ERB in-situ than 
without (Mean: 6.69cm versus 6.34cm, p=0.019). Superior-
inferior extent of SVs was significantly greater with ERB in-
situ (Mean: 2.6cm versus 2.0cm, p=0.0014). SV volumes were 
not significantly affected by ERB presence. 
Conclusions: One perceived benefit of ERB use in prostate 
radiotherapy is reducing rectal dosage. This is by firstly 
enabling a smaller PTV and secondly by pushing posterior 
rectum further from the high dose field. For intermediate or 
high risk patients who require full SV treatment this benefit 
may be negated by unfavourable positioning of the SV 
relative to the rectum. Here we show that the presence of an 
ERB causes increased lateral and superior-inferior spread of 
the SV, along with increased A-P overlap with the rectum. 
These previously undescribed anatomical alterations may 
influence planning of intermediate and high risk prostate 
cancer patients with ERB in-situ. Specifically, we hypothesise 
that increased A-P overlap may limit sparing of the posterior 
rectum when undertaking full length seminal vesicle 
irradiation. An on-going planning study at our institution will 
investigate this hypothesis. 
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Purpose/Objective: The rate of biochemical failure after 
primary external-beam radiation therapy (EBRT) in prostate 
cancer is still not negligible, around 33%. Management of 
prostate cancer relapses after EBRT is still undefined. Re-
irradiation schedules have been explored in different tumor 
sites. In this report, we present our preliminary experience of 
re-irradiation using SBRT for localized prostate cancer 
failure. 
Materials and Methods: Between March 2011 and April 2014, 
robotic SBRT was administered to patients previously treated 
with external-beam radiation therapy to a median dose of 72 
Gy (range, 45–76.5Gy) and with biochemical failure 
corresponding to a local in-field recurrence of prostate 
cancer. All patients underwent a pelvis MRI to confirm the 
recurrence and a total body staging using a 18F-choline 
positron emission tomography. The prescription dose 
consisted of five fractions of 7.25 Gy to a total dose of 36.25 
Gy. Efficacy was evaluated based on biochemical response 
and toxicity was evaluated according to CTCAE v.4.0 
questionnaires and International Prostate Symptom Score. 
Results: Seventeen patients were treated (five urethrovesical 
anastomosis lesions, nine lesions within the prostate, and 
three in residual seminal vesicles) and followed for a median 
6 months (mean, 9.4 months, range, 2.5–39.4 months). 
Median time between the first EBRT of prostate cancer and 
the first day of CyberKnife® treatment was 123 months 
(range, 38–398 months). A biochemical response was 
observed in 16 of the 17 evaluable patients (94.1%) and no in-
field progression was reported. Only one patient had a 
biochemical failure 5 months after the treatment, correlating 
to metastatic progression without evidence of local 
recurrence. Treatment was well tolerated, with five cases of 
genitourinary or gastrointestinal acute grade 1 toxicities . No 
grade ≥ 2 or other acute toxicities were reported. 
Conclusions: Stereotactic Body Re-irradiation Therapy using 
CyberKnife® after failed EBRT showed favorable results in 
terms of in-field local and biochemical control. Toxicity was 
low and acceptable. Further prospective studies are needed 
to confirm these results to select patient and to evaluate the 
introduction of androgen deprivation therapy. 
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Is the short course ADT with 76Gy IGRT appropriate for 
intermediate and high risk prostate cancer? 
